Introduction and Objective: Diabetes mellitus (DM) is a major risk factor for cognitive decline and dementia, whereas physical activity (PA) may mitigate this risk. However, the combined effects of PA and DM on cognitive function and brain structure remain unclear. We examined whether PA modifies associations of DM with mild cognitive impairment (MCI) and hippocampal […]
Read MoreAuthor: sugaradmin
1344-OR: Near- and Long-Term Improvements in A1C and CGM Metrics with Dexcom CGM Use in over 7,000 Adults with Type 2 Diabetes
Introduction and Objective: There are limited data evaluating both A1C and CGM metrics on a population level. This study assessed Dexcom CGM use on these measures in adults with T2D on non-insulin (NIT), non-intensive insulin (NIIT) and intensive insulin (IIT) therapies.Methods: Truveta EHR data linked at the individual level to Dexcom CGM data were analyzed […]
Read More1324-OR: A β-klotho Antibody Conjugated to GLP-1/GCG/GIP Triple Agonist Demonstrates Robust Body Weight Reduction and Metabolic Improvement in Obese Rodents and Nonhuman Primates
Introduction and Objective: Obesity is a major driver of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), conditions with substantial unmet medical need. This study aimed to characterize XWDAPC-1, a novel long-acting β-klotho antibody-GLP-1/GCG/GIP quadragonist, for its metabolic efficacy and pharmacological profile.Methods: The in vitro activity of XWDAPC-1 was evaluated using cell-based […]
Read More1323-OR: Zenagamtide Targets Key Feeding-Related Brain Regions and Induces Weight Loss by Preferentially Reducing Consumption of Unhealthy Solid and Liquid Diets in Rats
Introduction and Objective: An unhealthy diet is associated with obesity, cardiovascular disease and death. Zenagamtide (previously amycretin) is a novel unimolecular GLP1-, amylin- and calcitonin receptor agonist that decreased body weight by up to 24.3% in patients with obesity. As it is unknown if zenagamtide also promotes healthier food choices, we investigated zenagamtide’s distribution to […]
Read More1337-OR: The HOPE Study: An Immersive Telehealth Solution for Older Adults with Type 2 Diabetes
Introduction and Objective: Type 2 diabetes (T2DM) places older adults at risk of unhealthy aging and cognitive decline. Diabetes self-management education and support (DSME/S) is effective but underutilized. We conducted a two-arm randomized trial (DSME/S delivery via an immersive, 3D virtual environment (HOPE) versus a waitlist control group) to assess 6-month changes in glucose control […]
Read More1336-OR: A Lactate-PFKL Lactylation Positive Circuit Promotes the Progression of MASLD
Introduction and Objective: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a major global health challenge with limited effective pharmacological therapies. Although lysine lactylation has emerged as an important regulator of metabolic homeostasis, whether lactylation of the key glycolytic enzyme phosphofructokinase liver type (PFKL) drives MASLD progression and the underlying mechanisms remain obscure.Methods: Quantitative lactylome and […]
Read More1292-OR: Cardiovascular Outcomes Associated with GLP-1 Receptor Agonist Use among Adults with Type 1 Diabetes and Overweight or Obesity: A Target Trial Emulation Using Real-World EHR Data
Introduction and Objective: Evidence for GLP-1RA-associated cardiovascular benefits in type 1 diabetes (T1D) remains scarce. Using a target trial emulation, we assessed the impact of GLP-1RA use on cardiovascular outcomes in a high-risk cohort of adults with T1D and overweight or obesity.Methods: We emulated a target trial using electronic health records from Epic COSMOS database. […]
Read More1331-OR: Hepatic IRS1 as a Therapeutic Target in Metabolic Dysfunction–Associated Liver Disease (MASLD): AI/ML-Driven Genetic Discovery and In Vivo Therapeutic Validation
Introduction and Objective: MASLD is a common polygenic condition, but current GWASs have only identified 14 loci due to a lack of scalable, clinically relevant phenotypes.Methods: Using machine learning on four UKBB data modalities (MRI, DXA, plasma metabolites, blood biomarkers; n=25,474 to 262,927), we predicted liver fat (LF) and adipose tissue volume (ATV), increasing statistical […]
Read More1302-OR: Diabetes Nurse Practitioner–Led Management in Transitional Care Center Reduced 90-Day Utilization and Costs in High-Risk Patients
Introduction and Objective: The organization’s transitional care center (TCC) has reduced overall rehospitalizations. Initiative evaluated whether DM nurse practitioner (NP) led post-discharge management in TCC, coupled with CHW support with SDOH barriers, reduces 90-day healthcare utilization and costs among people hospitalized with diabetes, compared to 90 days prior to index admission.Methods: In 2025, DM NP […]
Read More1325-OR: Deficient β-Cell Reserve and Exocrine Insufficiency Synergistically Drive Glycemic Variability in Chronic Pancreatitis
Introduction and Objective: Post-pancreatitis diabetes mellitus (PPDM-C) is characterized by dual exocrine and endocrine failure. However, the impact of exocrine insufficiency (PEI) on β-cell reserve and glycemic variability remains underdefined. This study aims to elucidate the characteristics of islet function in CP and the influence of exocrine status on glucose homeostasis.Methods: We analyzed 148 CP […]
Read More